首页> 外文期刊>PLOS Neglected Tropical Diseases >Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects
【24h】

Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects

机译:含有HLA类-I和II类限制性表位的多表位肽的设计,衍生自免疫原性Leishmania蛋白,以及在固化皮肤LeishManiaisis受试者中诱导CD4 +和CD8 + T细胞应答的评价

获取原文
           

摘要

The control of leishmaniasis, a neglected tropical disease of public health importance, caused by protozoan parasites of the genus Leishmania, mainly relies on chemotherapy, which is highly toxic. Currently, there is no vaccine against human leishmaniasis. Peptide-based vaccines consisting of T cell epitopes identified within proteins of interest by epitope predictive algorithms are a promising strategy for vaccine development. Here, we identified multi-epitope peptides composed of HLA-I and -II-restricted epitopes, using immunoinformatic tools, within Leishmania proteins previously described as potential vaccine candidates. We showed that multi-epitope peptides used as pools were able to activate IFN producing CD4+ as well as CD8+ T cells, both required for parasite elimination. In addition, granzyme B-producing CD4+ T cells, bifunctional CD4+ IFN+/TNF-+ and/or TNF-+/IL-2+ T cells as well as CD4+ and CD8+ central memory T cells, all involved in Leishmania infection control, were significantly increased in response to multi-epitope peptide stimulation. As far as we know, no study has described the detection of both CD4+ and CD8+ T cell populations in response to stimulation by both HLA-I and II-restricted peptides in humans. The immunogenic HLA-I and -II-restricted multi-epitope peptides identified in this study could constitute potential vaccine candidates against human leishmaniasis.
机译:Leishmaniaisis的控制是由Leishmania属的原生动物寄生虫引起的忽略热带疾病,主要依赖于化疗,这具有剧毒性。目前,没有针对人类利什曼病的疫苗。由表位预测算法的蛋白质中鉴定的T细胞表位组成的基于肽的疫苗是疫苗发育的有希望的策略。在此,我们鉴定了使用免疫整理工具的HLA-1和-II限制表位组成的多表位肽,所述免疫蛋白质在预先描述为潜在疫苗候选物中。我们展示使用用作池的多表位肽能够激活IFN,其产生CD4 +以及寄生虫所需的CD8 + T细胞。此外,产生CD4 + T细胞的Granzyme B-生长CD4 + TN / TNF-+和/或TNF - + / IL-2 + T细胞以及CD4 +和CD8 +中央记忆T细胞,所有涉及Leishmania感染控制响应多表位肽刺激而显着增加。据我们所知,响应于人类HLA-I和II限制肽的刺激,没有研究过的检测到了CD4 +和CD8 + T细胞群。本研究中鉴定的免疫原性HLA-I和-II限制的多表位肽可构成对人类利什曼病的潜在疫苗候选者。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号